Source author record

Kevin Leder

Kevin Leder appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

10works
8topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

10 published item(s)

preprint2020arXiv

Mutation timing in a spatial model of evolution

Motivated by models of cancer formation in which cells need to acquire $k$ mutations to become cancerous, we consider a spatial population model in which the population is represented by the $d$-dimensional torus of side length $L$. Initially, no sites have mutations, but sites with $i-1$ mutations acquire an $i$th mutation at rate $μ_i$ per unit area. Mutations spread to neighboring sites at rate $α$, so that $t$ time units after a mutation, the region of individuals that have acquired the mutation will be a ball of radius $αt$. We calculate, for some ranges of the parameter values, the asymptotic distribution of the time required for some individual to acquire $k$ mutations. Our results, which build on previous work of Durrett, Foo, and Leder, are essentially complete when $k = 2$ and when $μ_i = μ$ for all $i$.

preprint2020arXiv

Understanding the role of phenotypic switching in cancer drug resistance

The emergence of acquired drug resistance in cancer represents a major barrier to treatment success. While research has traditionally focused on genetic sources of resistance, recent findings suggest that cancer cells can acquire transient resistant phenotypes via epigenetic modifications and other non-genetic mechanisms. Although these resistant phenotypes are eventually relinquished by individual cells, they can temporarily 'save' the tumor from extinction and enable the emergence of more permanent resistance mechanisms. These observations have generated interest in the potential of epigenetic therapies for long-term tumor control or eradication. In this work, we develop a mathematical model to study how phenotypic switching at the single-cell level affects resistance evolution in cancer. We highlight unique features of non-genetic resistance, probe the evolutionary consequences of epigenetic drugs and explore potential therapeutic strategies. We find that even short-term epigenetic modifications and stochastic fluctuations in gene expression can drive long-term drug resistance in the absence of any bona fide resistance mechanisms. We also find that an epigenetic drug that slightly perturbs the average retention of the resistant phenotype can turn guaranteed treatment failure into guaranteed success. Lastly, we find that combining an epigenetic drug with an anti-cancer agent can significantly outperform monotherapy, and that treatment outcome is heavily affected by drug sequencing.

preprint2016arXiv

Optimizing chemoradiotherapy to target multi-site metastatic disease and tumor growth

The majority of cancer-related fatalities are due to metastatic disease. In chemoradiotherapy, chemotherapeutic agents are administered along with radiation to increase damage to the primary tumor and control systemic disease such as metastasis. This work introduces a mathematical model to obtain optimal drug and radiation protocols in a chemoradiotherapy scheduling problem with the objective of minimizing metastatic cancer cell populations at multiple potential sites while maintaining a minimum level of damage to the primary tumor site. We derive closed-form expressions for an optimal chemotherapy fractionation regimen. A dynamic programming framework is used to determine the optimal radiotherapy fractionation regimen. Results show that chemotherapeutic agents do not change the optimal radiation fractionation regimens, and vice-versa. Interestingly, we observe that regardless of radio-sensitivity parameters, hypo-fractionated schedules are optimal solutions for the radiotherapy fractionation problem. Furthermore, it is optimal to immediately start radiotherapy. However, for chemotherapy, we find that the structure of the optimal schedule depends on model parameters such as chemotherapy-induced cell-kill at primary and metastatic sites, as well as the ability of primary tumor cells to initiate successful metastasis at different body sites. We quantify the trade-off between the new and traditional objectives of minimizing the metastatic population size and maximizing the tumor control probability, respectively, for a cervical cancer case. The trade-off information indicates the potential for significant reduction in the metastatic population with minimal loss in primary tumor control.

preprint2016arXiv

Rare-event Analysis for Extremal Eigenvalues of white Wishart matrices

In this paper we consider the extreme behavior of the extremal eigenvalues of white Wishart matrices, which plays an important role in multivariate analysis. In particular, we focus on the case when the dimension of the feature p is much larger than or comparable to the number of observations n, a common situation in modern data analysis. We provide asymptotic approximations and bounds for the tail probabilities of the extremal eigenvalues. Moreover, we construct efficient Monte Carlo simulation algorithms to compute the tail probabilities. Simulation results show that our method has the best performance amongst known approximation approaches, and furthermore provides an efficient and accurate way for evaluating the tail probabilities in practice.

preprint2015arXiv

Minimizing Metastatic Risk in Radiotherapy Fractionation Schedules

Metastasis is the process by which cells from a primary tumor disperse and form new tumors at distant anatomical locations. The treatment and prevention of metastatic cancer remains an extremely challenging problem. This work introduces a novel biologically motivated objective function to the radiation optimization community that takes into account metastatic risk instead of the status of the primary tumor. In this work, we consider the problem of developing fractionated irradiation schedules that minimize production of metastatic cancer cells while keeping normal tissue damage below an acceptable level. A dynamic programming framework is utilized to determine the optimal fractionation scheme. We evaluated our approach on a breast cancer case using the heart and the lung as organs-at-risk (OAR). For small tumor $α/β$ values, hypo-fractionated schedules were optimal, which is consistent with standard models. However, for relatively larger $α/β$ values, we found the type of schedule depended on various parameters such as the time when metastatic risk was evaluated, the $α/β$ values of the OARs, and the normal tissue sparing factors. Interestingly, in contrast to standard models, hypo-fractionated and semi-hypo-fractionated schedules (large initial doses with doses tapering off with time) were suggested even with large tumor $α$/$β$ values. Numerical results indicate potential for significant reduction in metastatic risk.

preprint2015arXiv

Robust and probabilistic optimization of dose schedules in radiotherapy

We consider the effects of parameter uncertainty on the optimal radiation schedule in the context of the linear-quadratic model. Our interest arises from the observation that if inter-patient variations in OAR and tumor sensitivities to radiation or sparing factor of the OAR are not accounted for during radiation scheduling, the performance of the therapy may be strongly degraded or the OAR may receive a substantially larger dose than the maximum threshold. This paper proposes two radiation scheduling concepts to incorporate inter-patient variability into the scheduling optimization problem. The first approach is a robust formulation that formulates the problem as a conservative model that optimizes the worst case dose scheduling that may occur. The second method is a probabilistic approach, where the model parameters are given by a set of random variables. This formulation insures that our constraints are satisfied with a given probability, and that our objective function achieves a desired level with a stated probability. We used a transformation to reduce the resulting optimization problem to two dimensions. We showed that the optimal solution lies on the boundary of the feasible region and we used a branch and bound algorithm to find the global optimal solution. We observed that if the number of fractions in the optimal conventional schedule is the same as the robust and stochastic solutions, it is preferable to administer equal or smaller total dose. In addition if there exist more (fewer) treatment sessions in the probabilistic or robust solution compared to the conventional schedule, a reduction in total dose squared (total dose) will be expected. Finally, we performed numerical experiments in the setting of head-and-neck tumors to reveal the effect of parameter uncertainty on optimal schedules and to evaluate the sensitivity of the model to the choice of key model parameters.

preprint2013arXiv

Dynamics of cancer recurrence

Mutation-induced drug resistance in cancer often causes the failure of therapies and cancer recurrence, despite an initial tumor reduction. The timing of such cancer recurrence is governed by a balance between several factors such as initial tumor size, mutation rates and growth kinetics of drug-sensitive and resistance cells. To study this phenomenon we characterize the dynamics of escape from extinction of a subcritical branching process, where the establishment of a clone of escape mutants can lead to total population growth after the initial decline. We derive uniform in-time approximations for the paths of the escape process and its components, in the limit as the initial population size tends to infinity and the mutation rate tends to zero. In addition, two stochastic times important in cancer recurrence will be characterized: (i) the time at which the total population size first begins to rebound (i.e., become supercritical) during treatment, and (ii) the first time at which the resistant cell population begins to dominate the tumor.

preprint2013arXiv

Multifocality and recurrence risk: a quantitative model of field cancerization

Primary tumors often emerge within genetically altered fields of premalignant cells that appear histologically normal but have a high chance of progression to malignancy. Clinical observations have suggested that these premalignant fields pose high risks for emergence of secondary recurrent tumors if left behind after surgical removal of the primary tumor. In this work, we develop a spatio-temporal stochastic model of epithelial carcinogenesis, combining cellular reproduction and death dynamics with a general framework for multi-stage genetic progression to cancer. Using this model, we investigate how macroscopic features (e.g. size and geometry of premalignant fields) depend on microscopic cellular properties of the tissue (e.g.\ tissue renewal rate, mutation rate, selection advantages conferred by genetic events leading to cancer, etc). We develop methods to characterize how clinically relevant quantities such as waiting time until emergence of second field tumors and recurrence risk after tumor resection. We also study the clonal relatedness of recurrent tumors to primary tumors, and analyze how these phenomena depend upon specific characteristics of the tissue and cancer type. This study contributes to a growing literature seeking to obtain a quantitative understanding of the spatial dynamics in cancer initiation.

preprint2010arXiv

Analysis of a Splitting Estimator for Rare Event Probabilities in Jackson Networks

We consider a standard splitting algorithm for the rare-event simulation of overflow probabilities in any subset of stations in a Jackson network at level n, starting at a fixed initial position. It was shown in DeanDup09 that a subsolution to the Isaacs equation guarantees that a subexponential number of function evaluations (in n) suffice to estimate such overflow probabilities within a given relative accuracy. Our analysis here shows that in fact O(n^{2β+1}) function evaluations suffice to achieve a given relative precision, where β is the number of bottleneck stations in the network. This is the first rigorous analysis that allows to favorably compare splitting against directly computing the overflow probability of interest, which can be evaluated by solving a linear system of equations with O(n^{d}) variables.

preprint2010arXiv

Evolutionary dynamics of tumor progression with random fitness values

Most human tumors result from the accumulation of multiple genetic and epigenetic alterations in a single cell. Mutations that confer a fitness advantage to the cell are known as driver mutations and are causally related to tumorigenesis. Other mutations, however, do not change the phenotype of the cell or even decrease cellular fitness. While much experimental effort is being devoted to the identification of the different functional effects of individual mutations, mathematical modeling of tumor progression generally considers constant fitness increments as mutations are accumulated. In this paper we study a mathematical model of tumor progression with random fitness increments. We analyze a multi-type branching process in which cells accumulate mutations whose fitness effects are chosen from a distribution. We determine the effect of the fitness distribution on the growth kinetics of the tumor. This work contributes to a quantitative understanding of the accumulation of mutations leading to cancer phenotypes.